Control of emesis in R-CHOP (Rituximab (R) - Cyclophosphamide (C), Doxorubicin (H), Vincristine (O), Prednisolone (P)

Not Applicable

Withdrawn

• Conditions: ausea and Vomiting in R-CHOP patients with Non-Hodgkin Lymphoma; Nausea and Vomiting in R-CHOP patients with Non-Hodgkin Lymphoma; Cancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma

• Registration Number: ACTRN12611001269921
• Lead Sponsor: Australasian Leukaemia and Lymphoma Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-12-12
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Withdrawn
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Chemotherapy-naive or those who have not received chemotherapy in the last 12 months;

Histologically confirmed diagnosis of NHL;

Intended to receive (R)-CHOP every 14 or 21 days for a minimum of 3 cycles;

Able to provide informed consent;

Are reasonably expected to be able to complete the CINV diary.

Exclusion Criteria

Women who are pregnant or lactating;

Previous exposure to chemotherapy, excluding oral alkylator therapy or single agent rituximab more than 12 months previously;

Prior radiotherapy within 12 months;

Use of concomitant medication with Orap (pimozide), Seldane (terfenadine), Hismanal (astemizole), or Propulsid (cisapride);

Any other clinically important abnormalities as determined by the investigator that may interfere with his or her participation in or compliance with the study;

Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. This condition must be discussed with the patient prior to signing consent and registration in the trial;

Age < 18 years.

Study & Design

• Study Type: Observational
• Study Design: Not specified